Edition:
United States

Gilead Sciences Inc (GILD.OQ)

GILD.OQ on NASDAQ Stock Exchange Global Select Market

75.51USD
21 Sep 2018
Change (% chg)

$0.68 (+0.91%)
Prev Close
$74.83
Open
$74.95
Day's High
$75.93
Day's Low
$74.77
Volume
5,108,962
Avg. Vol
2,230,748
52-wk High
$89.53
52-wk Low
$64.27

Latest Key Developments (Source: Significant Developments)

Gilead, Galapagos Announce Tortuga Phase 2 Study Of Filgotinib In Ankylosing Spondylitis Achieves Primary Endpoint
Thursday, 6 Sep 2018 01:01am EDT 

Sept 6 (Reuters) - Galapagos NV : :GILEAD AND GALAPAGOS ANNOUNCE TORTUGA PHASE 2 STUDY OF FILGOTINIB IN ANKYLOSING SPONDYLITIS ACHIEVES PRIMARY ENDPOINT.ADVERSE EVENTS GENERALLY MILD OR MODERATE IN SEVERITY AND WERE REPORTED IN EQUAL PROPORTION OF PATIENTS IN FILGOTINIB AND PLACEBO GROUPS.  Full Article

Gilead Enters Licensing Agreement With Trianni For Use Of Trianni Transgenic Human Monoclonal Antibody Discovery Platform
Tuesday, 4 Sep 2018 04:05pm EDT 

Sept 4 (Reuters) - Gilead Sciences Inc ::GILEAD ENTERS LICENSING AGREEMENT WITH TRIANNI FOR USE OF TRIANNI TRANSGENIC HUMAN MONOCLONAL ANTIBODY DISCOVERY PLATFORM.GILEAD SCIENCES INC - NO FINANCIAL DETAILS WERE DISCLOSED.  Full Article

Sierra Oncology Acquires Momelotinib From Gilead Sciences
Wednesday, 22 Aug 2018 07:00am EDT 

Aug 22 (Reuters) - Sierra Oncology Inc ::SIERRA ONCOLOGY ACQUIRES MOMELOTINIB, AN INVESTIGATIONAL JANUS KINASE (JAK) 1/2 AND ACTIVIN RECEPTOR TYPE 1 (ACVR1) INHIBITOR FOR MYELOFIBROSIS, FROM GILEAD SCIENCES.SIERRA ONCOLOGY INC - WILL PAY GILEAD A $3 MILLION UPFRONT FEE FOR MOMELOTINIB AND POTENTIAL AGGREGATE MILESTONE PAYMENTS OF UP TO $195 MILLION.SIERRA ONCOLOGY INC - SIERRA WILL ASSUME ALL CURRENTLY ONGOING CLINICAL STUDIES WITH MOMELOTINIB FOLLOWING A TRANSITION PERIOD..SIERRA - TO ALSO PAY GILEAD ROYALTIES ON ANY SALES OF MOMELOTINIB, WHICH WILL BE TIERED BASED ON COMMERCIAL SUCCESS & RANGE FROM MID-TEENS TO HIGH-TWENTIES.  Full Article

Gilead Sciences Says China Drug Administration Approves Epclusa
Wednesday, 30 May 2018 01:00am EDT 

May 30 (Reuters) - Gilead Sciences Inc ::GILEAD SCIENCES INC - CHINA DRUG ADMINISTRATION APPROVES EPCLUSA(SOFOSBUVIR/VELPATASVIR), GILEAD'S PAN-GENOTYPIC TREATMENT FOR CHRONIC HEPATITIS C VIRUS INFECTION.GILEAD SCIENCES INC - EPCLUSA IS FIRST PAN-GENOTYPIC HCV SINGLE TABLET REGIMEN (STR) APPROVED IN CHINA..  Full Article

Gilead: Natco And Teva Requested FDA Permission To Make Generic Version Of Sovaldi - SEC Filing
Tuesday, 27 Feb 2018 06:41am EST 

Feb 27 (Reuters) - Gilead Sciences Inc ::GILEAD SCIENCES INC SAYS IN FEBRUARY 2018, CO RECEIVED NOTICES FROM NATCO PHARMA LIMITED AND TEVA PHARMA - SEC FILING.GILEAD SCIENCES INC - NATCO PHARMA LIMITED,TEVA EACH SUBMITTED ANDA TO FDA REQUESTING PERMISSION TO MANUFACTURE AND MARKET GENERIC VERSION OF SOVALDI.GILEAD SCIENCES - TEVA ALLEGES THAT NINE PATENTS ASSOCIATED WITH SOFOSBUVIR INVALID, UNENFORCEABLE AND/OR WILL NOT BE INFRINGED BY TEVA’S MANUFACTURE.GILEAD SCIENCES-NATCO PHARMA ALLEGES THAT TWO PATENTS ASSOCIATED WITH SOFOSBUVIR INVALID,UNENFORCEABLE AND/OR WILL NOT BE INFRINGED BY NATCO’S MANUFACTURE.  Full Article

EMA Says Gilead Pulls Application To Extend Use Of Zydelig Drug ‍​
Friday, 23 Feb 2018 07:25am EST 

Feb 23 (Reuters) - EU MEDICINES AGENCY :APPLICATION TO EXTEND USE OF GILEAD SCIENCES ZYDELIG DRUG FOR TREATMENT OF CHRONIC LYMPHOCYTIC LEUKAEMIA WITHDRAWN ‍​‍​.  Full Article

Kite, Sangamo Therapeutics Announce Collaboration To Develop Next-Generation Engineered Cell Therapies For Treatment Of Cancer
Thursday, 22 Feb 2018 07:00am EST 

Feb 22 (Reuters) - Sangamo Therapeutics Inc ::KITE, A GILEAD COMPANY, AND SANGAMO THERAPEUTICS ANNOUNCE COLLABORATION TO DEVELOP NEXT-GENERATION ENGINEERED CELL THERAPIES FOR THE TREATMENT OF CANCER.SANGAMO THERAPEUTICS - KITE TO RECEIVE EXCLUSIVE LICENSE TO LEVERAGE SANGAMO'S GENE EDITING TECHNOLOGY IN ALLOGENEIC AND AUTOLOGOUS CELL THERAPY PROGRAMS IN ONCOLOGY.SANGAMO THERAPEUTICS INC - UNDER TERMS OF AGREEMENT, SANGAMO WILL RECEIVE AN UPFRONT PAYMENT OF $150 MILLION.SANGAMO THERAPEUTICS INC - UNDER TERMS, SANGAMO IS ELIGIBLE TO RECEIVE UP TO $3.01 BILLION IN POTENTIAL PAYMENTS.SANGAMO THERAPEUTICS INC - KITE WILL BE RESPONSIBLE FOR AGREED UPON EXPENSES INCURRED BY SANGAMO.SANGAMO THERAPEUTICS INC - CO WOULD ALSO RECEIVE TIERED ROYALTIES ON SALES OF POTENTIAL FUTURE PRODUCTS RESULTING FROM COLLABORATION.  Full Article

Kite And Sangamo Therapeutics Announce Collaboration To Develop Cell Therapies For Treatment Of Cancer
Thursday, 22 Feb 2018 07:00am EST 

Feb 22 (Reuters) - Sangamo Therapeutics Inc ::KITE, A GILEAD COMPANY, AND SANGAMO THERAPEUTICS ANNOUNCE COLLABORATION TO DEVELOP NEXT-GENERATION ENGINEERED CELL THERAPIES FOR THE TREATMENT OF CANCER.SANGAMO THERAPEUTICS INC - SANGAMO WILL RECEIVE AN UPFRONT PAYMENT OF $150 MILLION AND IS ELIGIBLE TO RECEIVE UP TO $3.01 BILLION IN POTENTIAL PAYMENTS.SANGAMO THERAPEUTICS INC - KITE WILL BE RESPONSIBLE FOR ALL DEVELOPMENT, MANUFACTURING AND COMMERCIALIZATION OF PRODUCTS UNDER COLLABORATION.  Full Article

Shionogi says ViiV Healthcare files patent infringement litigation against Gilead Sciences over bictegravir
Thursday, 8 Feb 2018 02:06am EST 

Feb 8 (Reuters) - Shionogi & Co Ltd <4507.T>:Says it announced that ViiV Healthcare, the global specialist HIV company majority-owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, has filed patent infringement litigation against Gilead Sciences Inc. over bictegravir in the United States and Canada.The United States case is filed in the U.S. District Court for the District of Delaware and the patent is U.S patent No. 8,129,385.The Canadian case is filed in the Canadian Federal Court in Toronto and the patent is Canadian Patent No. 2,606,282..  Full Article

Gilead Sciences Says FDA Approves Biktarvy For Treatment Of HIV-1 Infection
Wednesday, 7 Feb 2018 02:22pm EST 

Feb 7 (Reuters) - Gilead Sciences Inc ::U.S. FOOD AND DRUG ADMINISTRATION APPROVES GILEAD’S BIKTARVY® (BICTEGRAVIR, EMTRICITABINE, TENOFOVIR ALAFENAMIDE) FOR TREATMENT OF HIV-1 INFECTION.GILEAD SCIENCES INC - BIKTARVY HAS A BOXED WARNING IN ITS PRODUCT LABEL REGARDING RISK OF POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B.GILEAD SCIENCES - ‍ADDITIONAL CLINICAL TRIALS OF BIKTARVY ONGOING, INCLUDING A DEDICATED STUDY IN WOMEN; PLANS TO PRESENT DATA FROM STUDIES IN 2018​.GILEAD SCIENCES - APPROVAL OF BIKTARVY SUPPORTED BY DATA FROM 4 ONGOING PHASE 3 STUDIES INCLUDING STUDIES 1489 & 1490 IN TREATMENT-NAÏVE HIV-1 INFECTED ADULTS.GILEAD SCIENCES - APPROVAL OF BIKTARVY SUPPORTED BY DATA FROM 4 ONGOING PHASE 3 STUDIES INCLUDING STUDIES 1844 & 1878 IN VIROLOGICALLY SUPPRESSED ADULTS.  Full Article

UPDATE 1-Galapagos, Gilead bask in $4-6 bln new drug sales hope

LONDON, Sept 12 Strong results for an experimental drug that promises to disrupt the rheumatoid arthritis market lifted shares in Belgian-Dutch firm Galapagos to an all-time high on Wednesday, as analysts forecast multibillion-dollar sales.